Eli Lilly posted robust quarterly financial results driven by flagship injectables, though clinical nuances in its oral obesity pipeline tempered investor enthusiasm.

Eli Lilly posted significant revenue gains driven by unprecedented global demand for its blockbuster treatments Mounjaro and Zepbound, solidifying its leadership in the metabolic therapeutics market.

A dramatic shift in federal oversight permitting certain unapproved peptides has rattled pharmaceutical giants while igniting a boom for alternative wellness markets.

Healthcare equities navigate margin scrutiny, Medicare Advantage reimbursement adjustments, and strategic biopharma acquisitions as investors reposition for sector resilience.